NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 [Yahoo! Finance]
Neuropace, Inc. (NPCE)
Company Research
Source: Yahoo! Finance
— American Academy of Neurology (AAN) presentation featured 12- and 18-month NAUTILUS data, the first randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) — — Growing body of high-quality clinical evidence reinforces the RNS System's differentiated position across focal and generalized epilepsy — MOUNTAIN VIEW, Calif., April 27, 2026 BUSINESS WIRE )--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS ® System Post-Approval Study (PAS) in Neurology , alongside the Company's recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meeting. Together, these milestones underscore the breadth and strength of NeuroPace's clinical evidence leadership in epilepsy. The
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026Business Wire
- NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026Business Wire
- NeuroPace to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness Wire
- How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative [Yahoo! Finance]Yahoo! Finance
- NeuroPace (NPCE) was upgraded by Wells Fargo & Company to "strong-buy".MarketBeat
NPCE
Earnings
- 3/3/26 - Beat
NPCE
Sec Filings
- 4/21/26 - Form ARS
- 4/21/26 - Form DEF
- 3/25/26 - Form 4
- NPCE's page on the SEC website